SCHEMBL7270168

SCHEMBL7270168

Nc1nc2c([nH]1)c(=O)n(CC1CCCC1)c(=O)n2CC1CCCC1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 8/20 0.89
PDE4B Q07343 8/20 0.89
PDE4C Q08493 8/20 0.89
PDE4D Q08499 8/20 0.89
PDE5A O76074 7/20 0.89
ADORA1 P30542 9/20 0.51
ADORA2A P29274 7/20 0.51
ADORA2B P29275 7/20 0.51
ADORA3 P0DMS8 3/20 0.51
SIRT1 Q96EB6 1/20 0.48
SIRT3 Q9NTG7 1/20 0.48
SIRT5 Q9NXA8 1/20 0.48
MEN1 O00255 1/20 0.46
GMNN O75496 1/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
TSHR P16473 1/20 0.46
PMP22 Q01453 1/20 0.46
KMT2A Q03164 1/20 0.46
HIF1A Q16665 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7268220 0.99 PDE4A (0.87) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7269780 0.97 PDE4A (0.89) PDE4APDE4BPDE4CPDE4DPDE5A
Cipamfylline SCHEMBL26990 0.94 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7021179 0.82 PDE5A (0.61) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7269747 0.80 PDE4A (0.59) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7269993 0.79 PDE4A (0.57) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7032150 0.79 ADORA1 (0.64) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7269486 0.77 PDE4A (0.59) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7809025 0.77 PDE4A (0.70) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7026234 0.77 PDE4A (0.70) PDE4APDE4BPDE4CPDE4DPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0389282-B1 Xanthinederivatives, process for their preparation and their pharmaceutical use SMITHKLINE BEECHAM PHARMA GMBH (DE) 2002-02-20 EP claimed
EP-1120417-A2 Xanthine derivatives for the treatment of cerebrovascular disorders SMITHKLINE BEECHAM PHARMA GmbH (DE) 2001-08-01 EP claimed
US-5981535-A FOR TREATMENT OF ALLERGIC DISORDERS ASSOCIATED WITH ATOPY, BRONCHODILATION TO TREAT DISORDERS OF THE RESPIRATORY TRACT IN A MAMMAL SMITHKLINE BEECHAM P.L.C. (GB) 1999-11-09 US claimed
US-5734051-A TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY BEECHAM GROUP (GB) 1998-03-31 US claimed
EP-0389282-A2 Xanthinederivatives, process for their preparation and their pharmaceutical use BEECHAM - WUELFING GmbH & Co. KG (DE) 1990-09-26 EP claimed